Cecilia Giampietro

Padova, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.

Ixekizumab Treatment Persistence in Psoriatic Arthritis: Response to Joaquin et al.

Journal: Journal of psoriasis and psoriatic arthritis

Published: February 26, 2026

Does Prior Exposure Affect Retention? A Real-World, Multicentre Assessment of IL-17 Inhibitor Cycling in Psoriatic Arthritis.

Does Prior Exposure Affect Retention? A Real-World, Multicentre Assessment of IL-17 Inhibitor Cycling in Psoriatic Arthritis.

Journal: Rheumatology and therapy

Published: December 22, 2025

Six months predictors of DAPSA Remission With Guselkumab in Psoriatic Arthritis in a Multicenter Real-World Study.

Six months predictors of DAPSA Remission With Guselkumab in Psoriatic Arthritis in a Multicenter Real-World Study.

Journal: Scientific reports

Published: December 14, 2025

Comparative effectiveness of cycling versus swapping to IL-17 inhibitors after first TNF inhibitor failure in Psoriatic Arthritis: A real-world multicenter study.

Comparative effectiveness of cycling versus swapping to IL-17 inhibitors after first TNF inhibitor failure in Psoriatic Arthritis: A real-world multicenter study.

Journal: BMC rheumatology

Published: June 25, 2025

Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study.

Drug retention of TNF versus IL-23 inhibitors in psoriatic arthritis: a multicenter real-life cohort study.

Journal: Therapeutic advances in musculoskeletal disease

Published: June 23, 2025

Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort.

Filgotinib Effectiveness in Rheumatoid Arthritis: Observational Analysis of a Large Multicenter Cohort.

Journal: Rheumatology and therapy

Published: June 20, 2025

Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort Study.

Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort Study.

Journal: Mediterranean journal of rheumatology

Published: May 11, 2025

Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort Study.

Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort Study.

Journal: Mediterranean journal of rheumatology

Published: May 11, 2025

Guselkumab effectiveness in real-world settings: observations from an Italian multicentre study.

Guselkumab effectiveness in real-world settings: observations from an Italian multicentre study.

Journal: Rheumatology advances in practice

Published: April 27, 2025

Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study.

Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study.

Journal: Journal of psoriasis and psoriatic arthritis

Published: January 07, 2025

Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.

Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy.

Journal: Arthritis care & research

Published: May 22, 2012

Anti-Interleukin-1 Agents in Adult Onset Still's Disease.

Anti-Interleukin-1 Agents in Adult Onset Still's Disease.

Journal: International journal of inflammation

Published: January 09, 2012

Showing 1-12 of 13

Last Updated: 09/26/2026